GABATHER AB (PUBL) SK-44
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more
GABATHER AB (PUBL) SK-44 (5J2) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GABATHER AB (PUBL) SK-44 (5J2) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GABATHER AB (PUBL) SK-44 - Net Assets Trend (None–None)
This chart illustrates how GABATHER AB (PUBL) SK-44's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GABATHER AB (PUBL) SK-44 (None–None)
The table below shows the annual net assets of GABATHER AB (PUBL) SK-44 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GABATHER AB (PUBL) SK-44's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GABATHER AB (PUBL) SK-44 Competitors by Market Cap
The table below lists competitors of GABATHER AB (PUBL) SK-44 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Phoenix Solar Aktiengesellschaft
HM:PS4
|
$48.17K |
|
Central Natural Resources Inc
PINK:CTNR
|
$48.19K |
|
TRIPLEPOINT VEN.GR.DL-01
F:6JS
|
$48.21K |
|
Infimer Ltd
TA:INFR
|
$48.22K |
|
Atlas Honda Ltd
KAR:ATLH
|
$48.14K |
|
180060
KO:180060
|
$48.14K |
|
EMBASSY OFFICE PARKS REIT UNITS
NSE:EMBASSY
|
$48.12K |
|
B.M.P. PHARMA TRAD (BMP.SG)
STU:BMP
|
$48.09K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GABATHER AB (PUBL) SK-44's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GABATHER AB (PUBL) SK-44's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GABATHER AB (PUBL) SK-44 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GABATHER AB (PUBL) SK-44's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GABATHER AB (PUBL) SK-44 (5J2) | €- | N/A | N/A | $48.15K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |